Cingulate shares plans to resubmit its ADHD candidate CTx-1301 to the FDA, following a CRL tied to CMC information requests
News|Articles|September 30, 2026
The Psychiatric Pipeline in Review: Quarter 3, 2026
Author(s)Leah Kuntz
Explore Q3 2026 psych pipeline highlights—wins, setbacks, top disorders, and breakthrough ADHD, TRD, schizophrenia and Alzheimer therapies to watch.
Advertisement
Advertisement
The third quarter of 2026 had several prominent developments in the psychiatric treatment pipeline. Here, learn more about what percentage of that news was positive vs negative, what disease states were most prominently featured, and what treatments you should keep an eye on.
Related to this article
In the second positive phase 3 trial of lumateperone (Caplyta) for bipolar mania, participants saw improved manic symptoms vs placebo as early as day 3.
Lipocine has dosed the first participant in BLOOM, their phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression.
Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Check out our pipeline updates from October!
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
Advertisement
Advertisement